ASKA Pharmaceutical Co.,Ltd.

Investor Relations

Financial Statements

Consolidated Balance Sheets

 

Accounts As of March 31,2016 As of March 31,2017
Current assets 26,878 37,059
Cash and deposits 5,462 14,761
Notes and accounts receivable 8,566 9,485
Merchandise and finished goods 7,777 6,472
Other 5,072 6,340
Fixed assets 30,599 29,067
Property, plant and equipment 13,801 12,829
Intangible assets 3,296 3,491
Investments and other assets 13,501 12,746
Investment in securities 8,985 8,714
Other 4,515 4,031
Total assets 57,478 66,126

Unit: million yen

Accounts As of March 31,2016 As of March 31,2017
Current liabilities 10,992 16,253
Long-term liabilities 10,524 10,361
Liabilities 21,517 26,615
Shareholders,capital 34,398 36,965
Common stock 1,197 1,197
Additional paid-in capital 851 851
Retained earnings 34,759 37,312
Treasury stock △2,410 △2,396
Valuation,translation adjustments and others 1,562 2,545
Unrealized gain on securities 1,984 2,726
Adjustment total sum to affect the retirement bonus △422 △180
Total net assets 35,961 39,511
Total liabilities and net assets 57,478 66,126

Consolidated Statements of Income

Unit: million yen

Accounts FY2015 FY2016
Net Sales 43,125 48,527
Cost of sales 26,070 29,614
Gross profit 17,144 18,913
Selling,general and administrative expenses 15,861 17,119
Operating income 1,283 1,793
Non-operating income 389 441
Non-operating expenses 150 232
Ordinary income 1,522 2,002
Special interest 213 2,558
Extraordinary loss and minority interests 287 1,260
Income before income taxes 1,448 3,300
income taxes 746 356
Minority interests in income before income taxes 701 2,944
Minority interests in income - -
Net income 701 2,944

Consolidated Statements of Cash Flows

(Fiscal years ended March 31)Unit: million yen

Accounts FY2015 FY2016
Cash flows from operating activities △1,349 12,063
Cash flows from investing activities △6,776 △378
Cash flows from financing activities 4,013 △2,384
Effect of exchange rate changes on cash and cash equivalents △0 △0
Increase in cash and cash equivalents △4,112 9,299
Cash and cash equivalents at beginning of the year 9,574 5,462
Cash and cash equivalents at end of the year 5,462 14,761

Capital expenditure and R & D expenses.

Annual Report

2017

ASUKA Report Download
"ASKA REPORT"
Download

Press Release

Information Lists